Literature DB >> 34006473

Emerging concepts in PD-1 checkpoint biology.

Kristen E Pauken1, James A Torchia2, Apoorvi Chaudhri3, Arlene H Sharpe4, Gordon J Freeman5.   

Abstract

The PD-1 pathway is a cornerstone in immune regulation. While the PD-1 pathway has received considerable attention for its role in contributing to the maintenance of T cell exhaustion in chronic infection and cancer, the PD-1 pathway plays diverse roles in regulating host immunity beyond T cell exhaustion. Here, we discuss emerging concepts in the PD-1 pathway, including (1) the impact of PD-1 inhibitors on diverse T cell differentiation states including effector and memory T cell development during acute infection, as well as T cell exhaustion during chronic infection and cancer, (2) the role of PD-1 in regulating Treg cells, NK cells, and ILCs, and (3) the functions of PD-L1/B7-1 and PD-L2/RGMb/neogenin interactions. We then discuss the emerging use of neoadjuvant PD-1 blockade in the treatment of early-stage cancers and how the timing of PD-1 blockade may improve clinical outcomes. The diverse binding partners of PD-1 and its associated ligands, broad expression patterns of the receptors and ligands, differential impact of PD-1 modulation on cells depending on location and state of differentiation, and timing of PD-1 blockade add additional layers of complexity to the PD-1 pathway, and are important considerations for improving the efficacy and safety of PD-1 pathway therapeutics.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cancer immunotherapy; Immune regulation; Neoadjuvant; PD-1 pathway; T cell exhaustion

Mesh:

Substances:

Year:  2021        PMID: 34006473      PMCID: PMC8545711          DOI: 10.1016/j.smim.2021.101480

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  209 in total

1.  Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection.

Authors:  Tao Wu; Yinghong Hu; Young-Tae Lee; Keith R Bouchard; Alexandre Benechet; Kamal Khanna; Linda S Cauley
Journal:  J Leukoc Biol       Date:  2013-09-04       Impact factor: 4.962

Review 2.  T follicular regulatory (Tfr) cells: Dissecting the complexity of Tfr-cell compartments.

Authors:  Válter R Fonseca; Filipa Ribeiro; Luis Graca
Journal:  Immunol Rev       Date:  2019-03       Impact factor: 12.988

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

5.  Blockade of RGMb inhibits allergen-induced airways disease.

Authors:  Sanhong Yu; Krystle M Leung; Hye-Young Kim; Sarah E Umetsu; Yanping Xiao; Lee A Albacker; Hyun-Jun Lee; Dale T Umetsu; Gordon J Freeman; Rosemarie H DeKruyff
Journal:  J Allergy Clin Immunol       Date:  2019-01-29       Impact factor: 10.793

Review 6.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

Authors:  Rik Derynck; Ying E Zhang
Journal:  Nature       Date:  2003-10-09       Impact factor: 49.962

7.  PD-1 regulates KLRG1+ group 2 innate lymphoid cells.

Authors:  Samuel Taylor; Yuefeng Huang; Grace Mallett; Chaido Stathopoulou; Tania C Felizardo; Ming-An Sun; Evelyn L Martin; Nathaniel Zhu; Emma L Woodward; Martina S Elias; Jonathan Scott; Nick J Reynolds; William E Paul; Daniel H Fowler; Shoba Amarnath
Journal:  J Exp Med       Date:  2017-05-10       Impact factor: 14.307

8.  High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors.

Authors:  Jolanda Brummelman; Emilia M C Mazza; Giorgia Alvisi; Federico S Colombo; Andrea Grilli; Joanna Mikulak; Domenico Mavilio; Marco Alloisio; Francesco Ferrari; Egesta Lopci; Pierluigi Novellis; Giulia Veronesi; Enrico Lugli
Journal:  J Exp Med       Date:  2018-08-28       Impact factor: 14.307

9.  PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity.

Authors:  Jianshu Wei; Can Luo; Yao Wang; Yelei Guo; Hanren Dai; Chuan Tong; Dongdong Ti; Zhiqiang Wu; Weidong Han
Journal:  J Immunother Cancer       Date:  2019-08-07       Impact factor: 13.751

10.  Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.

Authors:  Helge Frebel; Veronika Nindl; Reto A Schuepbach; Thomas Braunschweiler; Kirsten Richter; Johannes Vogel; Carsten A Wagner; Dominique Loffing-Cueni; Michael Kurrer; Burkhard Ludewig; Annette Oxenius
Journal:  J Exp Med       Date:  2012-12-10       Impact factor: 14.307

View more
  12 in total

Review 1.  TCR-sequencing in cancer and autoimmunity: barcodes and beyond.

Authors:  Kristen E Pauken; Kaitlyn A Lagattuta; Benjamin Y Lu; Liliana E Lucca; Adil I Daud; David A Hafler; Harriet M Kluger; Soumya Raychaudhuri; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2022-01-25       Impact factor: 16.687

Review 2.  Lineage Reprogramming of Effector Regulatory T Cells in Cancer.

Authors:  Michael L Dixon; Jonathan D Leavenworth; Jianmei W Leavenworth
Journal:  Front Immunol       Date:  2021-07-28       Impact factor: 7.561

Review 3.  Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.

Authors:  Inna Serganova; Sanjukta Chakraborty; Samuel Yamshon; Yusuke Isshiki; Ryan Bucktrout; Ari Melnick; Wendy Béguelin; Roberta Zappasodi
Journal:  Front Cell Dev Biol       Date:  2022-01-07

Review 4.  Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer.

Authors:  Xia Qiu; Tianjiao Zhao; Ran Luo; Ran Qiu; Zhaoming Li
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

5.  Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor.

Authors:  Takashi Sato; Kiyoshi Takagi; Mitsunori Higuchi; Hiroko Abe; Michie Kojimahara; Miho Sagawa; Megumi Tanaki; Yasuhiro Miki; Takashi Suzuki; Hiroshi Hojo
Journal:  Acta Histochem Cytochem       Date:  2022-02-11       Impact factor: 1.938

6.  Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells.

Authors:  Christina Martins; Mariana Silva; Erik Rasbach; Praveen Singh; Yuta Itoh; Jason B Williams; Edith Statham; Anna Meurer; Daniela V Martinez; Anne Brandenburg; Markus V Heppt; Steven R Barthel; Tobias Schatton
Journal:  Sci Rep       Date:  2022-07-21       Impact factor: 4.996

7.  A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies.

Authors:  Melissa T Bu; Long Yuan; Alyssa N Klee; Gordon J Freeman
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2022-08-04

Review 8.  Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors.

Authors:  Peter L Stern; Tina Dalianis
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.048

Review 9.  Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1.

Authors:  Adam Mor; Marianne Strazza
Journal:  Front Cell Dev Biol       Date:  2022-01-03

10.  Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation.

Authors:  Leslie Chavez-Galan; Andy Ruiz; Karen Martinez-Espinosa; Hiram Aguilar-Duran; Martha Torres; Ramces Falfan-Valencia; Gloria Pérez-Rubio; Moises Selman; Ivette Buendia-Roldan
Journal:  Biomolecules       Date:  2022-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.